11:29 AM EST - Bausch Health Companies Inc. : Said its Ortho Dermatologics subsidiary announced that the Journal of Drugs in Dermatology has published results of two Phase 3 randomized controlled trials (Studies 1 and 2) examining the safety and efficacy of BRYHALITM* (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent** corticosteroid, in the treatment of moderate-to-severe plaque psoriasis. Bausch Health Companies Inc.
shares T.BHC are trading up $0.52 at $35.45.
